---
figid: PMC6990905__ijbsv16p0529g008
figtitle: UA reduction by empagliflozin
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
pmcid: PMC6990905
filename: ijbsv16p0529g008.jpg
figlink: pmc/articles/PMC6990905/figure/F8/
number: F8
caption: Proposed mechanism of UA reduction by empagliflozin. Empagliflozin treatment
  improved hyperuricemia by promoting UA excretion through up-regulating ABCG2 expression
  in diabetes with hyperuricemia. Furthermore, empagliflozin treatment promoted the
  phosphorylation of AMPK, AKT and CREB and further activated ABCG2 by facilitating
  CREB binding to the promoter of ABCG2 to induce transcription.
papertitle: Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB
  Signaling Pathway in Type 2 Diabetic Mice.
reftext: Yun-hong Lu, et al. Int J Biol Sci. 2020;16(3):529-542.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.953966
figid_alias: PMC6990905__F8
figtype: Figure
redirect_from: /figures/PMC6990905__F8
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6990905__ijbsv16p0529g008.html
  '@type': Dataset
  description: Proposed mechanism of UA reduction by empagliflozin. Empagliflozin
    treatment improved hyperuricemia by promoting UA excretion through up-regulating
    ABCG2 expression in diabetes with hyperuricemia. Furthermore, empagliflozin treatment
    promoted the phosphorylation of AMPK, AKT and CREB and further activated ABCG2
    by facilitating CREB binding to the promoter of ABCG2 to induce transcription.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SNF4Agamma
  - AMPKalpha
  - CrebB
  - CrebA
  - anon-70Dc
  - Empagliflozin
  - uric acid
  - Diabetes
  - hyperuricemia
---
